StreetInsider.com News Articles

Form 4 Candel Therapeutics, For: Sep 10 Filed by: Tak Paul Peter

Fri, 11 Sep 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260911/27053841.html

Form 144 Candel Therapeutics, Filed by: Tak Paul Peter

Thu, 10 Sep 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260910/27048983.html

Form 4 Candel Therapeutics, For: Sep 08 Filed by: Zimmermann Martine

Thu, 10 Sep 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260910/27048764.html

Form 3 Candel Therapeutics, For: Sep 08 Filed by: Zimmermann Martine

Thu, 10 Sep 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260910/27048738.html

Form 8-K Candel Therapeutics, For: Sep 06

Thu, 10 Sep 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260910/27045592.html

Candel Therapeutics adds regulatory veteran to its board

Thu, 10 Sep 2026 08:05:14 -0400

Candel Therapeutics, Inc. (Nasdaq: CADL) announced the appointment of Martine Zimmermann, PharmD, to its board of directors, effective September 8, 2026.

Zimmermann currently serves as Executive Vice President, Head of Regulatory Affairs, Quality and Alliance Management at Inventiva S.A. Prior to that role, she was Senior Vice President, Head of Global Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, and spent more than 13 years at Alexion Pharma International in senior regulatory leadership positions. She earned her Doctor of Pharmacy degree from the University of Strasbourg.

The Needham, Massachusetts-based company said the appointment comes as it prepares to submit a Biologics License

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Thu, 10 Sep 2026 08:05:00 -0400

Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness

NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company’s Board of Directors (Board) effective September 8, 2026.

“Martine joins Candel at an important stage in our evolution, as we prepare for the

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Thu, 10 Sep 2026 08:05:00 -0400

Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness

“Martine joins Candel at an important stage in our evolution, as we prepare for the

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:05:00 -0400

NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company’s common stock, with a per share exercise price of $13.07.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:05:00 -0400

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics to Present at September Investor Conferences

Wed, 26 Aug 2026 08:05:00 -0400

NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.

Key Details:

Citi's 2026 Biopharma Back to School Conference (New York, NY)
Date/Time: Wednesday, September 9, 2026, at 10:00AM ET
Webcast Link: Citi / Candel Fireside

Candel Therapeutics to Present at September Investor Conferences

Wed, 26 Aug 2026 08:05:00 -0400

Key Details:

Citi's 2026 Biopharma Back to School Conference (New York, NY)
Date/Time: Wednesday, September 9, 2026, at 10:00AM ET
Webcast Link: Citi / Candel Fireside

Form 4 Candel Therapeutics, For: Aug 17 Filed by: Tyagarajan Seshu

Wed, 19 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26950495.html

Form 4 Candel Therapeutics, For: Aug 17 Filed by: Tyagarajan Seshu

Wed, 19 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26950495.html

Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu

Mon, 17 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26938467.html

Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu

Mon, 17 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26938467.html

Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker

Mon, 17 Aug 2026 12:22:54 -0400

Freedom Broker analyst Ilya Zubkov raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $15.00 (from $14.00) while maintaining a Buy rating.

The analyst comments "The key event of the quarter was the start of patient enrollment in the global registrational Phase III AURORA trial of CAN-2409 in NSCLC, alongside the publication of pivotal Phase III data that strengthened our confidence in the drug's approval potential. The company confirmed plans to file a BLA for CAN-2409 in localized prostate cancer in Q4'26 and continues to guide to a potential commercial launch in 2027. Operating expenses came in above our

Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker

Mon, 17 Aug 2026 12:22:54 -0400

Freedom Broker analyst Ilya Zubkov raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $15.00 (from $14.00) while maintaining a Buy rating.

Candel Therapeutics Inc. (CADL) PT Raised to $12 at BofA Securities

Fri, 14 Aug 2026 05:18:58 -0400

BofA Securities analyst Alec Stranahan raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $12.00 (from $9.00) while maintaining a Neutral rating.

Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c

Thu, 13 Aug 2026 08:58:17 -0400

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q2 EPS of ($0.52), $0.29 worse than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

Form 10-Q Candel Therapeutics, For: Jun 30

Thu, 13 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26917112.html

Form 10-Q Candel Therapeutics, For: Jun 30

Thu, 13 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26917112.html

Form 8-K Candel Therapeutics, For: Aug 13

Thu, 13 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26916971.html

Form 8-K Candel Therapeutics, For: Aug 13

Thu, 13 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26916971.html

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 08:05:00 -0400

Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Pivotal phase 3 clinical data published in The Lancet Oncology demonstrated a statistically significant improvement in disease-free survival with aglatimagene plus standard-of-care radiotherapy compared with radiotherapy alone in patients with localized, intermediate- to high-risk prostate cancer
Presented supportive clinical data from extended follow-up of the phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer in a plenary oral presentation at the American Urological Association (AUA) 2026 Annual